Proteome Sciences

Proteome Sciences is a pioneering, publicly traded proteomics company with a dual-revenue model combining high-margin reagent sales through a global ThermoFisher partnership with a full-service CRO business. Founded in 1994, it has established itself as a critical enabler in drug development by providing deep, quantitative protein analysis from discovery to clinical trials. Its strategy is centered on capitalizing on the growing demand for proteomic data in precision medicine, supported by its foundational intellectual property in multiplexed isobaric tagging technology.

Proprietary Tandem Mass Tag (TMT) isobaric labeling technology for multiplexed quantitative proteomics, coupled with a comprehensive suite of mass spectrometry-based discovery, targeted, and specialty proteomic service workflows.

Proteome Sciences competes in the proteomics CRO space against firms like Biognosys and Olink, differentiating via its TMT expertise and GCLP clinical services. In reagents, its TMT technology, distributed by market-leader ThermoFisher, holds a leading position against alternatives like iTRAQ, creating a defensible IP moat.